EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Zilebesiran and Hypertension: A Systematic Review and Meta-analysis

Mohamed Lemine, Saif Almuzainy, Rayan Aljubeh, Ahmad Alilo

Journal of the Saudi Heart Association · 26.12.2024 · 36 (4)

DOI: 10.37616/2212-5043.1408 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the Saudi Heart Association, online erschienen am 26.12.2024. Verfasst von Mohamed Lemine und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Zilebesiran is an investigational RNA interference therapeutic designed to lower blood pressure by targeting the hepatic production of angiotensinogen, the most upstream precursor of the renin–angiotensin–aldosterone system. This approach aims to offer long-lasting blood pressure control with potentially fewer doses compared to traditional antihypertensive medications. The objective of this systematic review and meta-analysis was to assess the antihypertensive efficacy of zilebesiran in patients with hypertension.

Methods

We conducted a search across PubMed, Cochrane Library, Ovid, EBSCO, up until July 2024. The eligible studies included randomized controlled trials that examined Zilebesiran versus placebo in hypertensive patients. These studies reported outcomes like reduction in 24-hour systolic blood pressure (SBP) from baseline, changes in plasma angiotensinogen (ATG) levels and office SBP at three months. Meta-analyses were carried out using RevMan.

Results

Our search identified 138 records, of which three randomized control trials (RCTs) with 1,145 patients met inclusion criteria, focusing on Zilebesiran versus placebo for primary hypertension. Quality assessment revealed two high-quality and one moderate-quality study. Pooled analysis showed Zilebesiran significantly reduced 24-hour systolic blood pressure (SBP) compared to placebo across all doses (MD -12.84, 95% CI -16.00 to -9.68, P < 0.00001), though heterogeneity was high for doses above 500 mg. Zilebesiran also significantly lowered plasma angiotensinogen and office SBP. Sensitivity analysis resolved some heterogeneity issues. Publication bias could not be assessed.

Conclusion

Zilebesiran effectively reduces 24-hour and office systolic blood pressure and plasma angiotensinogen, demonstrating significant antihypertensive benefits. Optimal dosing appears between 250-500 mg. Further research should explore patient-specific responses to enhance therapeutic efficacy and minimize side effects.

Schlagwörter

Stichwörter der Autor:innen

ALN-AGT01HypertensionZilebesiran

Autor:innen und Institutionen

  • College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.

Zitieren

APA

Lemine, M., Almuzainy, S., Aljubeh, R., & Alilo, A. (2024). Zilebesiran and Hypertension: A Systematic Review and Meta-analysis. Journal of the Saudi Heart Association, 36(4). https://doi.org/10.37616/2212-5043.1408

Vancouver

Lemine M, Almuzainy S, Aljubeh R, Alilo A. Zilebesiran and Hypertension: A Systematic Review and Meta-analysis. Journal of the Saudi Heart Association. 2024;36(4). doi:10.37616/2212-5043.1408

BibTeX
@article{Lemine2024,
  author = {Lemine, Mohamed and Almuzainy, Saif and Aljubeh, Rayan and Alilo, Ahmad},
  title = {Zilebesiran and Hypertension: A Systematic Review and Meta-analysis},
  journal = {Journal of the Saudi Heart Association},
  year = {2024},
  volume = {36},
  number = {4},
  doi = {10.37616/2212-5043.1408}
}
Kostenlos starten →